Catalysts About Roche Holding Roche Holding is a global healthcare group focused on pharmaceuticals and diagnostics, with a large late stage pipeline and extensive manufacturing and R&D infrastructure. What are the underlying business or industry changes driving this perspective?Read more

CHF 295

3.0% overvalued

AnalystLowTarget's

Fair Value

Revenue

-0.18% p.a.

Profit Margin

25.03%

Future PE

16.65x

Price in 2029

CHF 331.01

Trending Discussion

Snowflake Analysis

Undervalued with solid track record and pays a dividend.

1 Risk

5 Rewards

View Full Analysis

Roche Holding AG Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

Apr 23, 2026

: 16.19
: 74.49%
: 20.33%
: 83.5%

View Full Analysis

About ROP

Founded: 1896
Employees: 103249
CEO: Thomas Schinecker
WebsiteView website: www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.